IL253731A0 - Crystal forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1, 2,4-triazole-3-carboxamide - Google Patents
Crystal forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1, 2,4-triazole-3-carboxamideInfo
- Publication number
- IL253731A0 IL253731A0 IL253731A IL25373117A IL253731A0 IL 253731 A0 IL253731 A0 IL 253731A0 IL 253731 A IL253731 A IL 253731A IL 25373117 A IL25373117 A IL 25373117A IL 253731 A0 IL253731 A0 IL 253731A0
- Authority
- IL
- Israel
- Prior art keywords
- oxazepin
- tetrahydrobenzo
- carboxamide
- triazole
- oxo
- Prior art date
Links
- LYPAFUINURXJSG-AWEZNQCLSA-N 5-benzyl-n-[(3s)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1h-1,2,4-triazole-3-carboxamide Chemical compound N([C@H]1COC2=CC=CC=C2N(C1=O)C)C(=O)C(N=1)=NNC=1CC1=CC=CC=C1 LYPAFUINURXJSG-AWEZNQCLSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C223/00—Compounds containing amino and —CHO groups bound to the same carbon skeleton
- C07C223/04—Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115674P | 2015-02-13 | 2015-02-13 | |
| PCT/IB2016/050755 WO2016128936A1 (en) | 2015-02-13 | 2016-02-12 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL253731A0 true IL253731A0 (en) | 2017-09-28 |
Family
ID=55359562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253731A IL253731A0 (en) | 2015-02-13 | 2017-07-30 | Crystal forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1, 2,4-triazole-3-carboxamide |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10287280B2 (OSRAM) |
| EP (1) | EP3256467A1 (OSRAM) |
| JP (1) | JP2018505199A (OSRAM) |
| KR (1) | KR20170117472A (OSRAM) |
| CN (1) | CN107207485A (OSRAM) |
| AU (1) | AU2016217496B2 (OSRAM) |
| BR (1) | BR112017017411A2 (OSRAM) |
| CA (1) | CA2976172A1 (OSRAM) |
| IL (1) | IL253731A0 (OSRAM) |
| RU (1) | RU2017131862A (OSRAM) |
| WO (1) | WO2016128936A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3366684B1 (en) | 2015-10-23 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
| WO2019123219A1 (en) * | 2017-12-20 | 2019-06-27 | Glaxosmithkline Intellectual Property Development Limited | Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| DK3788045T3 (da) | 2018-05-03 | 2023-06-26 | Rigel Pharmaceuticals Inc | RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf |
| BR112020022420A2 (pt) | 2018-05-03 | 2021-03-02 | Rigel Pharmaceuticals, Inc. | composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para produzir o composto |
| WO2020234716A1 (en) * | 2019-05-17 | 2020-11-26 | Glaxosmithkline Intellectual Property Development Limited | Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| JP7376218B2 (ja) | 2019-09-06 | 2023-11-08 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| MY198690A (en) | 2019-09-06 | 2023-09-16 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same |
| KR102824962B1 (ko) | 2019-11-07 | 2025-06-26 | 리겔 파마슈티칼스, 인크. | 헤테로시클릭 rip1 억제 화합물 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| TW202300490A (zh) | 2021-03-11 | 2023-01-01 | 美商雷傑製藥公司 | 雜環rip1激酶抑制劑 |
| KR20240132504A (ko) | 2022-01-12 | 2024-09-03 | 데날리 테라퓨틱스 인크. | (s)-5-벤질-n-(5-메틸-4-옥소-2,3,4,5-테트라하이드로피리도 [3,2-b][1,4]옥사제핀-3-일)-4h-1,2,4-트리아졸-3-카복사미드의 결정질 형태 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI648273B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
-
2016
- 2016-02-12 EP EP16704713.3A patent/EP3256467A1/en not_active Withdrawn
- 2016-02-12 JP JP2017542048A patent/JP2018505199A/ja active Pending
- 2016-02-12 CA CA2976172A patent/CA2976172A1/en not_active Abandoned
- 2016-02-12 BR BR112017017411A patent/BR112017017411A2/pt not_active Application Discontinuation
- 2016-02-12 US US15/548,500 patent/US10287280B2/en active Active
- 2016-02-12 CN CN201680010191.7A patent/CN107207485A/zh active Pending
- 2016-02-12 RU RU2017131862A patent/RU2017131862A/ru not_active Application Discontinuation
- 2016-02-12 WO PCT/IB2016/050755 patent/WO2016128936A1/en not_active Ceased
- 2016-02-12 KR KR1020177025358A patent/KR20170117472A/ko not_active Withdrawn
- 2016-02-12 AU AU2016217496A patent/AU2016217496B2/en not_active Ceased
-
2017
- 2017-07-30 IL IL253731A patent/IL253731A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017017411A2 (pt) | 2018-04-03 |
| CN107207485A (zh) | 2017-09-26 |
| KR20170117472A (ko) | 2017-10-23 |
| US20180022737A1 (en) | 2018-01-25 |
| CA2976172A1 (en) | 2016-08-18 |
| RU2017131862A (ru) | 2019-03-13 |
| US10287280B2 (en) | 2019-05-14 |
| WO2016128936A1 (en) | 2016-08-18 |
| AU2016217496B2 (en) | 2019-03-07 |
| EP3256467A1 (en) | 2017-12-20 |
| AU2016217496A1 (en) | 2017-08-17 |
| JP2018505199A (ja) | 2018-02-22 |
| RU2017131862A3 (OSRAM) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL253731A0 (en) | Crystal forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1, 2,4-triazole-3-carboxamide | |
| IL273730A (en) | crystalline forms | |
| CL2016003145A1 (es) | Compuestos de [1,2,4]triazol sustituido | |
| ZA201708699B (en) | Brk inhibitory compound | |
| IL247276A0 (en) | [1,2,4]-converted triazole and imidazole compounds as fungicides | |
| IL253473A0 (en) | Ototaxin inhibitory compounds | |
| IL249299A0 (en) | Modified [4,2,1]triazole and imidazole compounds as fungicides | |
| IL257757A (en) | Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | |
| ZA201608472B (en) | Substituted [1,2,4]triazole and imidazole compounds as fungicides | |
| HUE070241T2 (hu) | Kristályos, nagy modulusú termoplasztikus poliuretán | |
| IL273896A (en) | Crystal forms of 3-disubstituted 1, 2, 4-oxadiazole | |
| SG10201911417PA (en) | Crystalline compounds | |
| ZA201906464B (en) | Crystalline forms of (s)-afoxolaner | |
| IL265445A (en) | crystalline forms | |
| IL259556A (en) | Solid forms of substituted 6,5-dihydro-6-phenyl-benzo[f]isoquinoline-2-amine compounds | |
| PT3515454T (pt) | Forma polimórfica cristalina de 3-hidroxi-4,5-bis-benziloxi-6-benziloximetil-2-fenil-2-oxo-2lambda5-[1,2]oxafosfinano | |
| PL3350179T3 (pl) | Krystaliczne postacie | |
| HK40102359A (zh) | 结晶化合物 | |
| HK40099983A (zh) | 结晶化合物 | |
| ZA201902553B (en) | Crystalline forms | |
| GB201715010D0 (en) | Crystalline forms | |
| GB201704789D0 (en) | Crystalline compounds | |
| IL261795A (en) | Crystalline form | |
| GB201708856D0 (en) | Seletalisib crystalline forms | |
| HK1255019A1 (en) | Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds |